MedTrace Logo

Atherectomy By Laser Ablation With Turbo-Elite

NCT02307370 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2021-08-27

Study results available
· View outcomes & findings →

Summary

The primary objective for this study is to prove the safety and effectiveness of the Spectranetics Turbo-Elite catheter in atherectomy treatment for infrainguinal arteries with catheter to vessel sizing of at least 50%.

Conditions

  • Peripheral Arterial Disease
  • Peripheral Vascular Disease

Interventions

DEVICE

Turbo-Elite Laser Catheter

Application of laser energy to remove blockage

Sponsors & Collaborators

  • Spectranetics Corporation

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-11-30
Completion
2016-11-30
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02307370 on ClinicalTrials.gov